NCT03211416 2026-02-05
Sorafenib Tosylate and Pembrolizumab in Treating Patients With Advanced or Metastatic Liver Cancer
Roswell Park Cancer Institute
Phase 1/2 Completed
Clinical Trials
43 trialsNCT01658878 2025-12-24
CheckMate040
Bristol-Myers Squibb
Phase 1/2 Completed
NCT05091346 2025-10-24
A Study of E7386 in Combination With Pembrolizumab in Previously Treated Participants With Selected Solid Tumors
Eisai Inc.
Phase 1/2 Completed
NCT03126110 2025-08-14
Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies
Incyte Corporation
Phase 1/2 Completed
NCT01754987 2025-05-04
A Study of Vitamin C in the Treatment of Liver Cancer to Determine if it is Safe and Effective
Thomas Jefferson University
Phase 1/2 Completed
NCT03397654 2025-03-06
PETAL
Imperial College London
Phase 1/2 Completed
NCT03941873 2024-10-26
A Study to Investigate Sitravatinib as Monotherapy and in Combination With Tislelizumab in Participants With Unresectable Locally Advanced or Metastatic Hepatocellular Carcinoma or Gastric/Gastroesophageal Junction Cancer
BeiGene
Phase 1/2 Completed
NCT02325739 2024-10-21
FGF401 in HCC and Solid Tumors Characterized by Positive FGFR4 and KLB Expression
Novartis
Phase 1/2 Completed
NCT02509507 2024-08-06
MASTERKEY-318
Amgen
Phase 1/2 Completed
NCT02314052 2024-07-11
Phase Ib/2, Multicenter, Dose Escalation Study of DCR-MYC in Patients With Hepatocellular Carcinoma
Novo Nordisk A/S
Phase 1/2 Terminated
NCT02705105 2024-04-25
Study of Mogamulizumab + Nivolumab in Subjects w/Locally Advanced or Metastatic Solid Tumors
Kyowa Kirin Co., Ltd.
Phase 1/2 Completed
NCT02273362 2024-03-26
Erlotinib Hydrochloride in Preventing Liver Cancer in Patients With Cirrhosis of the Liver
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT03422679 2024-01-16
Study of CB-103 in Adult Patients With Advanced or Metastatic Solid Tumours and Haematological Malignancies
Cellestia Biotech AG
Phase 1/2 Terminated
NCT03684811 2023-11-18
A Study of FT-2102 in Patients With Advanced Solid Tumors and Gliomas With an IDH1 Mutation
Novo Nordisk A/S
Phase 1/2 Completed
NCT02279719 2023-11-15
A Study of BBI608 in Combination With Sorafenib, or BBI503 in Combination With Sorafenib in Adult Patients With Hepatocellular Carcinoma
Sumitomo Pharma America, Inc.
Phase 1/2 Completed
NCT04194801 2023-02-06
A Phase Ib/II Study of Fisogatinib(BLU-554) in Subjects With Hepatocellular Carcinoma
CStone Pharmaceuticals
Phase 1/2 Completed
NCT03648073 2023-01-10
[68Ga]DOTATATE-PET/MRI in Hepatocellular Carcinoma
University of Alabama at Birmingham
Phase 1/2 Completed
NCT01177397 2022-12-13
Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma
Celgene
Phase 1/2 Completed
NCT03241173 2022-09-27
A Study Exploring the Safety and Efficacy of INCAGN01949 in Combination With Immune Therapies in Advanced or Metastatic Malignancies
Incyte Corporation
Phase 1/2 Completed
NCT01988493 2022-08-24
Efficacy, Safety, and Pharmacokinetic of MSC2156119J in Asian Participants With Hepatocellular Carcinoma
Merck KGaA, Darmstadt, Germany
Phase 1/2 Completed
NCT02115373 2022-08-24
c-Met Second-Line Hepatocellular Carcinoma
Merck KGaA, Darmstadt, Germany
Phase 1/2 Completed
NCT02575339 2022-07-26
MLN0128 Compared to Sorafenib in Advanced or Metastatic Hepatocellular Carcinoma
Big Ten Cancer Research Consortium
Phase 1/2 Terminated
NCT00790218 2022-05-17
A Phase 1-2 Study of CF102 in Patients With Advanced Hepatocellular Carcinoma
Can-Fite BioPharma
Phase 1/2 Completed
NCT00867321 2022-04-19
Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer
Alliance for Clinical Trials in Oncology
Phase 1/2 Completed
NCT02178722 2022-02-14
Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers
Incyte Corporation
Phase 1/2 Completed
NCT03071094 2021-11-19
A Trial to Evaluate the Safety and Efficacy of the Combination of the Oncolytic Immunotherapy Pexa-Vec With the PD-1 Receptor Blocking Antibody Nivolumab in the First-line Treatment of Advanced Hepatocellular Carcinoma (HCC)
Transgene
Phase 1/2 Terminated
NCT01631552 2021-08-12
Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial Cancer
Gilead Sciences
Phase 1/2 Completed
NCT01271504 2021-05-12
E7050 in Combination With Sorafenib Versus Sorafenib Alone as First Line Therapy in Participants With Hepatocellular Carcinoma
Eisai Inc.
Phase 1/2 Completed
NCT01178411 2021-03-10
An Extension Protocol for Subjects Who Were Previously Enrolled in Other Tivantinib (ARQ 197) Protocols
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Phase 1/2 Completed
NCT01264705 2020-11-12
Study of Bavituximab and Sorafenib In Patients With Advanced Liver Cancer
University of Texas Southwestern Medical Center
Phase 1/2 Completed
NCT02560779 2020-07-17
Trial of TRC105 and Sorafenib in Patients With HCC
Tracon Pharmaceuticals Inc.
Phase 1/2 Completed
NCT02013778 2020-04-20
Phase 1-2 Trial HCQ Plus TACE in Unresectable HCC
Abramson Cancer Center at Penn Medicine
Phase 1/2 Terminated
NCT01853618 2019-12-10
Tremelimumab With Chemoembolization or Ablation for Liver Cancer
National Institutes of Health Clinical Center (CC)
Phase 1/2 Completed
NCT00946153 2019-02-01
Study of Lenvatinib (E7080) in Participants With Advanced Hepatocellular Carcinoma (HCC)
Eisai Inc.
Phase 1/2 Completed
NCT02828124 2019-01-30
A Study of the Safety and Tolerability of BMS-986183 in Patients With Liver Cancer
Bristol-Myers Squibb
Phase 1/2 Terminated
NCT01306058 2019-01-23
Sorafenib and TRC105 in Hepatocellular Cancer
National Institutes of Health Clinical Center (CC)
Phase 1/2 Completed
NCT00149396 2018-04-24
Safety & Efficacy of NV1020 in Colorectal Cancer Metastatic to the Liver
MediGene
Phase 1/2 Completed
NCT00321594 2017-11-06
Belinostat in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT00516165 2017-02-07
RAD001 in Advanced Hepatocellular Carcinoma
Massachusetts General Hospital
Phase 1/2 Completed
NCT01020812 2016-07-27
Combination SBRT With TACE for Unresectable Hepatocellular Carcinoma
Stanford University
Phase 1/2 Terminated
NCT01406574 2015-06-08
Phase I/II Study of OPB-31121 in Patients With Progressive Hepatocellular Carcinoma
Otsuka Pharmaceutical Co., Ltd.
Phase 1/2 Completed
NCT00862082 2013-08-23
Randomized Phase 1/2 Open-Label Trial of PR104 and Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC)
Proacta, Incorporated
Phase 1/2 Terminated
NCT00614913 2012-08-20
Proton Beam Therapy for Treatment of Hepatocellular Carcinoma
Loma Linda University
Phase 1/2 Completed